Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Roche Obtains FDA Clearance for Diagnostic Use of Its Digital Pathology Solution

NextEdge Admin

18 Jun 2024

2 min 15 sec

Roche announced today that its Roche Digital Pathology Dx slide scanner, the VENTANA DP 200, has received FDA 510(k) clearance. This system enhances pathology by enabling pathologists to review and interpret digital images of scanned slides, facilitating quicker diagnoses from any location.

Jill German, Roche Diagnostics' Head of Pathology Lab, highlighted that digital pathology streamlines workflows, enhancing lab efficiency and extending pathologists' reach to remote areas. Collaboration among pathologists is also bolstered, improving diagnostic accuracy and patient care.

Digital pathology transforms traditional histopathology by digitizing slide scanning, visualization, and analysis processes. Once tissue slides are scanned and converted into digital images, they can be shared and analyzed by pathologists. This capability aids in determining optimal treatments for cancer patients and supports more thorough analyses than traditional methods.

Roche is committed to advancing digital pathology through innovations like AI-based tools and its Roche Digital Pathology Open Environment. These initiatives aim to drive adoption and foster innovation in pathology.

Founded in 1896 in Basel, Switzerland, Roche has evolved into a global biotechnology leader and a pioneer in personalized healthcare and diagnostics. The company's dedication to scientific excellence and sustainability has been recognized consistently, including its long-standing presence in the Dow Jones Sustainability Indices.

Roche continues to invest in shaping the future of pathology by integrating research-oriented tools into routine clinical practices, thereby improving global healthcare delivery.